CN1952137B - Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology - Google Patents

Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology Download PDF

Info

Publication number
CN1952137B
CN1952137B CN200610015383A CN200610015383A CN1952137B CN 1952137 B CN1952137 B CN 1952137B CN 200610015383 A CN200610015383 A CN 200610015383A CN 200610015383 A CN200610015383 A CN 200610015383A CN 1952137 B CN1952137 B CN 1952137B
Authority
CN
China
Prior art keywords
leu
ile
thr
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200610015383A
Other languages
Chinese (zh)
Other versions
CN1952137A (en
Inventor
方佩华
陈慧
李宁
王少艳
谭建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Medical University General Hospital
Original Assignee
Tianjin Medical University General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Medical University General Hospital filed Critical Tianjin Medical University General Hospital
Priority to CN200610015383A priority Critical patent/CN1952137B/en
Publication of CN1952137A publication Critical patent/CN1952137A/en
Application granted granted Critical
Publication of CN1952137B publication Critical patent/CN1952137B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention discloses the expressing product of human thyrotropin receptor extracellular domain amino terminus gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-Nterminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.

Description

Human thyrotropin receptor extracellular region aminoterminal gene expression product and preparation method and the application of this product in enzyme immune technology
Technical field
The invention belongs to gene engineering technology field, be aminoterminal gene expression product and preparation method thereof in human thyrotropin receptor extracellular region aminoterminal, carboxyl terminal, interlude three fragments and this product enzyme exempt from and luminous enzyme immune technology in application.
Background technology
Autoimmune thyroid disease (AITD) is a class frequently-occurring disease, comprises Graves ' sick (GD), chronic lymphocytic thyroiditis (HT) etc., and its pathogenesis is not clear fully as yet so far.
Thyrotropin receptor (TSHR) is a kind of glycoprotein that exists on follicular epithelial cell (TEC) film, and it is with after thyrotropin (TSH) combines, and regulates the growth, differentiation of TEC and synthetic and discharge the function of Triiodothyronine.On E﹠H factor basis, the body's immunity ANOMALOUS VARIATIONS causes AITD, TSHR is one of main autoantigen of AITD, stimulate body to produce serum thyrotropin receptor antibody (TRAb), this autoantibody belongs to heterogeneous antibody, comprises thyroid stimulating antibody (TSAb) and Tiroidina blocking antibody (TSBAb), and the former simulates the TSH function, stimulate synthetic release of Triiodothyronine for a long time constantly and cause Graves ' disease, the function of appeal is hyperfunction; The latter combines with the TSHR specific site and stops combining and the performance of physiological action of TSH and TSHR, shows as hypothyroidism.TSHR belongs to g protein coupled receptor family, and it is comprised extracellular fragment, striden film section and very short born of the same parents' inner segment three parts by the glycoprotein that 764 amino acid are formed, and hydrophilic extracellular region is made up of 418 amino-acid residues, and this is distinguished by 9 exons codings.The antigenic determinant of TSH, TSAb and TSBAb mainly is distributed in TSHR extracellular fragment (TSHR-ecd), and TSHR-ecd is TSH performance physiological action or the morbific key link of TRAb.Therefore, the antigenic determinant of inquiring into TSHR helps to understand their 26S Proteasome Structure and Function, particularly at the corresponding antigens determinant of different autoantibodies, pathogenesis, AITD diagnosis typing, the curative effect of exploring AITD are judged and even treat all have tangible theory significance, crucial clinical value and good DEVELOPMENT PROSPECT.
Present research thinks that TSAb mainly is incorporated into the aminoterminal of TSHR-ecd (N-end), and it is the important target area of TSAb that the aa22-61 of report TSHR-ecd N-end is arranged; The target site of TSBAb then concentrates on the carboxyl terminal (C-end) of TSHR-ecd, and wherein Cys 301, Cys381 and Try 390 are TSBAb bonded key positions; Report to TSHR-interlude antigenic determinant is very limited. and the research of at present relevant TSHRAb antigenic determinant is mainly from gene elmination or replacement, the association reaction between the antiserum(antisera) in synthetic peptide and AITD patients serum and animal model source and the result of study of gene engineering expression product, but the above two are owing to lack or space conformation that can not correct response hTSHR-ecd, become the bottleneck that this field is launched further investigation as hTSHR proteantigen determinant research material and obtain hTSHR albumen. because the distribution of TSHR on the follicular epithelial cell film is very rare and extremely unstable, therefore, the TSHR that is difficult to directly to obtain from TEC q.s carries out correlative study; Though TSHR is in the eukaryotic system expression of having succeedd, and this system expression product overcomes the difficult problem of TSHR albumen space conformation, but it yields poorly, technology relative complex, shortcoming that production cost is high, and it expresses output still can't satisfy the research of TSHR antigenic determinant; Comparatively speaking, the prokaryotic expression system technology maturation, the output height, technology is simple, production cost is low, remaining this research and obtain the best means of a large amount of target proteins. Chinese scholars also successively uses different expression vectors to go out the hTSHR total length or the extracellular region protein of solubility at expression in escherichia coli in recent years, my chamber report in intestinal bacteria successful expression soluble T SHR-ecd albumen, also progressively improve through the output of repeatedly practising expression product. and since the two kinds of autoantibodies that on TSHR-ecd, distributing epitope, at present still be difficult to distinguish their definite site, after this fragment gene carried out rough separation and expressing, the result who carries out institute's acquisition of antigenic determinant again can synthetic peptide method gained result have more cogency. and people such as Japanese scholar Akira Nakai once were divided into the TSHR extracellular region two fragments and carried out prokaryotic expression, but up to now, still no-trump hTSHR extracellular region divides three sections (aminoterminals, carboxyl terminal and interlude) report of expressing.
External at present TRAb detection technique commonly used has two kinds: 1. radioreceptor assay, its shortcoming are can only survey TRAb can not differentiate TSAb and TSBAb.2. biological analysis: can distinguish TSAb and TSBAb, but complicated operation, unsuitable conventional the use.And its commodity medicine box is all very expensive, though domestic have an introduction, can not promote.Thereby create the detection TRAb of China oneself and the new technology that can distinguish to some extent TSAb and TSBAb very necessary.
Summary of the invention
The objective of the invention is to that TSHR-ecd cDNA is divided into three sections (hTSHR-N end, hTSHR-C end and hTSHR-M sections) and carry out respectively, particularly the hTSHR-N end carried out gene clone, expression vector establishment, E.coli prokaryotic expression, and be that antigen is set up TRAb (comprising TSAb, TSBAb) ELISA detection technique further with this genetically engineered fragment albumen.
The objective of the invention is to be achieved through the following technical solutions:
Inventor's thyrotropin receptor extracellular region aminoterminal, carboxyl terminal, interlude gene expression product wherein aminoterminal, carboxyl terminal are the recombinant fragment albumen with thyrotropin receptor protein antigenicity of people.Said aminoterminal hTSHR-N fragment is expressed and is obtained recombinant fragment albumen (TrxFus-hTSHR-N), and the Nucleotide of its cDNA and aminoacid sequence are:
ATG?GGG?TGT?TCG?TCT?CCA?CCC?TGC?GAG?TGC?CAT?CAG?GAG?GAG?GAC?TTC 211bp
Met?Gly?Cys?Ser?Ser?Pro?Pro?Cys?Glu?Cys?His?Gln?Glu?Glu?Asp?Phe 16AA
1 7 13
AGA?GTC?ACC?TGC?AAG?GAT?ATT?CAA?CGC?ATC?CCC?AGC?TTA?CCG?CCC?AGT 259bp
Arg?Val?Thr?Cys?lys?Asp?Ile?Gln?Arg?Ile?Pro?Ser?Leu?Pro?Pro?Ser?32AA
19 25 31
ACG?CAG?ACT?CTG?AAG?CTT?ATT?GAG?ACT?CAC?CTG?AGA?ACT?ATT?CCA?AGT?307bp
Thr?Gln?Thr?Leu?lys?Leu?Ile?Glu?Thr?His?Leu?Arg?Thr?Ile?Pro?Ser?48AA
37 43
CAT?GCA?TTT?TCT?AAT?CTG?CCC?AAT?ATT?TCC?AGA?ATC?TAC?GTA?TCT?ATA?355bp
His?Ala?Phe?Ser?Asn?Leu?Pro?Asn?Ile?Ser?Arg?Ile?Tyr?Val?Ser?Ile?64AA
49 55 61
GAT?GTG?ACT?CTG?CAG?CAG?CTG?GAA?TCA?CAC?TCC?TTC?TAC?AAT?TTG?AGT?403bp
Asp?Val?Thr?Leu?Gln?Gln?Leu?Glu?Ser?His?Ser?Phe?Tyr?Asn?Leu?Ser?80AA
67 73 79
AAA?GTG?ACT?CAC?ATA?GAA?ATT?CGG?AAT?ACC?AGG?AAC?TTA?ACT?TAC?ATA?451bp
lys?Val?Thr?His?Ile?Glu?Ile?Arg?Asn?Thr?Arg?Asn?Leu?Thr?Tyr?Ile?96AA
85 91
GAC?CCT?GAT?GCC?CTC?AAA?GAG?CTC?CCC?CAC?CTA?AAG?TTC?CTT?GGC?ATT?499bp
Asp?Pro?Asp?Ala?Leu?lys?Glu?Leu?Pro?His?Leu?lys?Phe?Leu?Gly?Ile?112AA
97 103 109
TTC?AAC?ACT?GGA?CTT?AAA?ATG?TTC?CCT?GAC?CTG?ACC?AAA?GTT?TAT?TCC?547bp
Phe?Asn?Thr?Gly?Leu?lys?Met?Phe?Pro?Asp?Leu?Thr?lys?Val?Tyr?Ser?128AA
115 121 127
ACT?GAT?ATA?TTC?TTT?ATA?CTT?GAA?ATT?ACA?GAC?AAC?CCT?TAC?ATG?ACG?595bp
Thr?Asp?Ile?Phe?Phe?Ile?Leu?Glu?Ile?Thr?Asp?Asn?Pro?Tyr?Met?Thr?144AA
133 139
TCA?ATC?CCT?GTG?AAT?GCT?TTT?CAG?GGA?CTA 625bp
Ser?Ile?Pro?Val?Asn?Ala?Phe?Gln?Gly?Leu 154AA
145 151 。
Human thyrotropin receptor extracellular region aminoterminal, carboxyl terminal, three kinds of expression products of interlude gene exist with the fusion rotein form, the fusion protein molecule amount is respectively 34.4kD, 29.8kD, (wherein recombinant protein is respectively 21.2kD to 30.1kD, 16.6kD, 16.9kD; Trx is 13.2kD).
The preparation method of human thyrotropin receptor extracellular region aminoterminal (also comprising carboxyl terminal, interlude) gene expression product, adopt the TRIzol single stage method, from the parathyroid tissue that Graves ' patient operative treatment downcuts, extract total RNA, synthetic and amplification hTSHR-N end (also having hTSHR-C end, the hTSHR-M section) encoding gene through RT-PCR, directed cloning inserts carrier pET102/D-His.The heat-shocked method is with constructed expression vector Transformed E .coli TOP10, screen positive bacterium colony, extract recombinant expression plasmid pET102/hTSHRn (also having pET102/hTSHRc, pET102/hTSHRm) recombinant expression plasmid and change in the e. coli bl21 (DE3), carry out prokaryotic expression.Expression condition is: with 0.4-1.2mML -1Isopropylthio β-D-galactoside (IPTG) is an inductor, 25 ℃-37 ℃, induces 1-12 hour.Adopt sex change Ni 2+-NTA affinitive layer purification system purifying through gradient dialysis, renaturation, concentrated, obtains TrxFus-hTSHRn (also having TrxFus-hTSHRc, TrxFus-hTSHRm) recombinant protein.
The present invention explores TSAb on human thyrotropin receptor extracellular region aminoterminal, carboxyl terminal, interlude gene expression product, the TSBAb antigenic determinant distributes, the TrxFus-hTSHRn and the TrxFus-hTSHRc that are rich in TSAb, TSBAb antigenic determinant are made antigen respectively, be applied to set up human serum TRAb (comprising TSAb, TSBAb) enzyme linked immunological absorption (ELISA) detection technique and setting up luminous enzyme immune technology.
Positively effect of the present invention:
1, at first the hTSHR extracellular region is divided three sections to carry out gene clone and express and successfully obtained the three sections goal gene and the warm albumen of recombinating thereof at home and abroad.
2, at home and abroad on three segmental gene engineering products, study first TSAb, TSBAb different fragments in conjunction with epi-position (being antigenic determinant) and distribute.TrxFus-hTSHRc and TrxFus-hTSHRn two target proteins have and Tiroidina blocking antibody (TSBAb) and pungency antibody (TSAb) bonded antigenicity, and wherein the former combines more responsively with TSBAb, illustrates that this fragment is that the TSBAb binding site is preponderated.
3, take the lead in utilizing the recombinant protein of hTSHR N, C two ends successfully set up two ELISA methods can detect human serum TRAb and can distinguish TSAb and TSBAb who preponderates, the method sensitivity, special, accurate, stable and tentatively be used for clinical, for the exploitation of AITD etiological diagnosis test kit is got ready.In addition, lay a good foundation for further inquiring into the biotechnological formulation that antigenic determinant and distribution thereof and research is used for the treatment of AITD.
Description of drawings
Fig. 1 is the evaluation of pcr amplification goal gene;
Fig. 2 is that the double digestion of recombinant plasmid pET 102-hTSHRn is identified;
Fig. 3 cuts evaluation for the enzyme of recombinant plasmid pET 102-hTSHRm;
Fig. 4 cuts evaluation for the enzyme of recombinant plasmid pET102-hTSHRc;
Fig. 5 is the influence of induction time to pET102-TSHRn expressing fusion protein output;
Fig. 6 is the SDS-PAGE electrophoresis of affinitive layer purification product;
Fig. 7 is the protein standard curve;
Fig. 8 is the influence of induction time to expressing fusion protein output;
Fig. 9 is the influence of induction time to expressing fusion protein output;
Figure 10 is that hTSHR-ecd aminoterminal prokaryotic expression protein immunocompetence is identified (Westernblot).
Embodiment
One, the structure and the evaluation of human thyrotropin receptor extracellular region aminoterminal, interlude and carboxyl terminal gene clone, expression plasmid
(1) human thyrotropin receptor extracellular region aminoterminal, interlude and carboxyl terminal gene clone
Employing TRIzol single stage method is synthetic human thyroid cDNA first chain of the total RNA reverse transcription of extraction from the parathyroid tissue of Graves ' patient operative treatment cutting-out, and increasing respectively with the capable RT-PCR of primer that designs voluntarily, hTSHR-N holds, hTSH-C holds and the hTSHR-M encoding gene.With the nucleic acid molecular weight standard is reference, identifies this pcr amplification product with 1.5% agarose gel electrophoresis, the result be presented at 462bp, 417bp and 405bp place visible respectively one clearly, special electrophoretic band, (see figure 1) conforms to expection gene fragment size.Among Fig. 1:
Swimming lane 1:DNA Marker;
Swimming lane 2:PCR hTSHRc amplified production;
Swimming lane 3:PCR hTSHRm amplified production;
Swimming lane 4:PCR hTSHR nAmplified production.
(2) recombinant expression plasmid pET102-hTSHR nStructure and evaluation:
With hTSHR nThe gene directed cloning inserts pET102/D-His carrier, recombinant expression plasmid called after pET102-hTSHR nThe heat-shocked method is transformed into expresses bacterium E.coli BL21.
1. the enzyme of recombinant plasmid pET102-hTSHRn is cut evaluation:
PET 102-hTSHRn recombinant expression vector is through Pst I single endonuclease digestion, cut the single band of 6770kb; Ssp I enzyme is cut, cut 1105bp and 5669bp two bands, (see figure 2) all is consistent with the Theoretical Calculation result.Among the figure:
1、2：DNA?Marker；
3: recombinant plasmid;
4:Pst I enzyme is cut recombinant plasmid;
5:Ssp I enzyme is cut recombinant plasmid.
2. the order-checking of recombinant plasmid pET 102-hTSHRn is identified:
With recombinant plasmid pET 102-hTSHRn is template, be sequencing primer with TrxFus, T7Reverse respectively, this recombinant plasmid is carried out partial sequence to be measured, measure the sequence that is about 700bp, the result shows the target gene fragment that this carrier is forgiven and Nagayama report sequence is in full accord, direction of insertion is correct, and is correctly identical with the upstream and downstream interface of pET102 carrier.
The Trx restriction enzyme site
TTC?CTC?GAC?GCT?AAC?CTG?GCC?GGC?TCT?GGA?TCC?GGT? GAT?GAC?GAT?GAC
Phe?Leu?Asp?Ala?Asn?Leu?Ala?Gly?Ser?Gly?Ser?Gly? Asp?Asp?Asp?Asp
Upstream Interface
AAG?CTG?GGA?ATT?GAT?CCC?TT C?ACC?ATG?GGG?TGT?TCG?TCT?CCA?CCC?TGC
Lys?Leu?Gly?Ile?Asp?Pro? Phe?Thr?Met?Gly?Cys?Ser?Ser?Pro?Pro?Cys
GAG?TGC?CAT?CAG?GAG?GAG?GAC?TTC?AGA?GTC?ACC?TGC?AAG?GAT?ATT?CAA
Glu?Cys?His?Gln?Glu?Glu?Asp?Phe?Arg?Val?Thr?Cys?lys?Asp?Ile?Gln
CGC?ATC?CCC?AGC?TTA?CCG?CCC?AGT?ACG?CAG?ACT?CTG?AAG?CTT?ATT?GAG
Arg?Ile?Pro?Ser?Leu?Pro?Pro?Ser?Thr?Gln?Thr?Leu?lys?Leu?Ile?Glu
ACT?CAC?CTG?AGA?ACT?ATT?CCA?AGT?CAT?GCA?TTT?TCT?AAT?CTG?CCC?AAT
Thr?His?Leu?Arg?Thr?Ile?Pro?Ser?His?Ala?Phe?Ser?Asn?Leu?Pro?Asn
ATT?TCC?AGA?ATC?TAC?GTA?TCT?ATA?GAT?GTG?ACT?CTG?CAG?CAG?CTG?GAA
Ile?Ser?Arg?Ile?Tyr?Val?Ser?Ile?Asp?Val?Thr?Leu?Gln?Gln?Leu?Glu
TCA?CAC?TCC?TTC?TAC?AAT?TTG?AGT?AAA?GTG?ACT?CAC?ATA?GAA?ATT?CGG
Ser?His?Ser?Phe?Tyr?Asn?Leu?Ser?lys?Val?Thr?His?Ile?Glu?Ile?Arg
AAT?ACC?AGG?AAC?TTA?ACT?TAC?ATA?GAC?CCT?GAT?GCC?CTC?AAA?GAG?CTC
Asn?Thr?Arg?Asn?Leu?Thr?Tyr?Ile?Asp?Pro?Asp?Ala?Leu?lys?Glu?Leu
CCC?CAC?CTA?AAG?TTC?CTT?GGC?ATT?TTC?AAC?ACT?GGA?CTT?AAA?ATG?TTC
Pro?His?Leu?lys?Phe?Leu?Gly?Ile?Phe?Asn?Thr?Gly?Leu?lys?Met?Phe
CCT?GAC?CTG?ACC?AAA?GTT?TAT?TCC?ACT?GAT?ATA?TTC?TTT?ATA?CTT?GAA
Pro?Asp?Leu?Thr?lys?Val?Tyr?Ser?Thr?Asp?Ile?Phe?Phe?Ile?Leu?Glu
ATT?ACA?GAC?AAC?CCT?TAC?ATG?ACG?TCA?ATC?CCT?GTG?AAT?GCT?TTT?CAG
Ile?Thr?Asp?Asn?Pro?Tyr?Met?Thr?Ser?Ile?Pro?Val?Asn?Ala?Phe?Gln
Downstream interface
GGA?CTA? AAG?GGC?GAG?CTC?AAG?CTT?GAA?GGT?AAG?CCT?ATC?CCT?AAC?CCT
Gly?Leu? Lys?Gly?Glu?Leu?Lys?Leu?Glu?Gly?Lys?Pro?Ile?Pro?Asn?Pro
The 6*His label
CTC?CTC?GGT?CTC?GAT?TCT?ACG?CGT?ACC?GGT? CAT?CAT?CAC? CAT?CAC?CAT
Leu?Leu?Gly?Leu?Asp?Ser?Thr?Arg?Thr?Gly? His?His?His? His?His?His
TGA?GTT?TGA?TCC?GGC?TGC?TAA?CAA?AGC?CCG?AAA?GGA?AGC?TGA?GTT?GGC
TGC?TGC?CAC?CGC?TGA?GCA?ATA?ACT?A
(3) structure of recombinant expression plasmid pET102-hTSHRm and evaluation:
With hTSHR mThe gene directed cloning inserts pET102/D-His carrier, recombinant expression plasmid called after pET102-hTSHR mThe heat-shocked method is transformed into expresses bacterium E.coli BL21.
1. the enzyme of recombinant plasmid pET102/hTSHRm is cut evaluation:
PET 102-hTSHRm recombinant expression vector is through Pst I and Stu I after enzyme is cut respectively, all cut the single band of 6770kb; Behind PstI+Stu I double digestion, cut 1530bp and 5191bp two bands, (seeing shown in Figure 3) all conforms to the Theoretical Calculation result.Among the figure:
1、2：DNA?Marker；
3: recombinant plasmid;
4:Pst I+Stu I double digestion recombinant plasmid;
5:Stu I single endonuclease digestion recombinant plasmid;
6:Pst I enzyme is cut recombinant plasmid.
2. the order-checking of recombinant plasmid pET 102-hTSHRm is identified:
With recombinant plasmid pET102-hTSHRm is template, with TrxFus is sequencing primer, this recombinant plasmid is carried out partial sequence to be measured, measure and comprise upstream and downstream interface, target gene fragment sequence at the interior 700bp of being about, the result shows that the sequence of reports such as target gene fragment and Nagayama is in full accord, direction of insertion is correct, correctly coincide with pET102 carrier upstream and downstream interface.
The Trx restriction enzyme site
TTC?CTC?GAC?GCT?AAC?CTG?GCC?GGC?TCT?GGA?TCC?GGT? GAT?GAC?GAT?GAC
Phe?Leu?Asp?Ala?Asn?Leu?Ala?Gly?Ser?Gly?Ser?Gly? Asp?Asp?Asp?Asp
Upstream Interface
AAG?CTG?GGA?ATT?GAT?CCC?TT C?ACC?AAC?CCT?TAC?ATG?ACG?TCA?ATC?CCT
Lys?Leu?Gly?Ile?Asp?Pro?Phe?Thr?Asn?Pro?Tyr?Met?Thr?Ser?Ile?Pro
GTG?AAT?GCT?TTT?CAG?GGA?CTA?TGC?AAT?GAA?ACC?TTG?ACA?CTG?AAG?CTG
Val?Asn?Ala?Phe?Gln?Gly?Leu?Cys?Asn?Glu?Thr?Leu?Thr?Leu?lys?Leu
TAC?AAC?AAC?GGC?TTT?ACT?TCA?GTC?CAA?GGA?TAT?GCT?TTC?AAT?GGG?ACA
Tyr?Asn?Asn?Gly?Phe?Thr?Ser?Val?Gln?Gly?Tyr?Ala?Phe?Asn?Gly?Thr
AAG?CTG?GAT?GCT?GTT?TAC?CTA?AAC?AAG?AAT?AAA?TAC?CTG?ACA?GTT?ATT
lys?Leu?Asp?Ala?Val?Tyr?Leu?Asn?lys?Asn?lys?Tyr?Leu?Thr?Val?Ile
GAC?AAA?GAT?GCA?TTT?GGA?GGA?GTA?TAC?AGT?GGA?CCA?AGC?TTG?CTG?GAC
Asp?lys?Asp?Ala?Phe?Gly?Gly?Val?Tyr?Ser?Gly?Pro?Ser?Leu?Leu?Asp
GTG?TCT?CAA?ACC?AGT?GTC?ACT?GCC?CTT?CCA?TCC?AAA?GGC?CTG?GAG?CAC
Val?Ser?Gln?Thr?Ser?Val?Thr?Ala?Leu?Pro?Ser?lys?Gly?Leu?Glu?His
CTG?AAG?GAA?CTG?ATA?GCA?AGA?AAC?ACC?TGG?ACT?CTT?AAG?AAA?CTT?CCA
Leu?lys?Glu?Leu?Ile?Ala?Arg?Asn?Thr?Trp?Thr?Leu?lys?lys?Leu?Pro
CTT?TCC?TTG?AGT?TTC?CTT?CAC?CTC?ACA?CGG?GCT?GAC?CTT?TCT?TAC?CCA
Leu?Ser?Leu?Ser?Phe?Leu?His?Leu?Thr?Arg?Ala?Asp?Leu?Ser?Tyr?Pro
AGC?CAC?TGC?TGT?GCT?TTT?AAG?AAT?CAG?AAG?AAA?ATC?AGA?GGA?ATC?CTT
Ser?His?Cys?Cys?Ala?Phe?lys?Asn?Gln?lys?lys?Ile?Arg?Gly?Ile?Leu
GAG?TCC?TTG?ATG?AGC?CAC?TGC?TGT?GCT?TTT?AAG?AAT?CAG?AAG?AAA?ATC
Glu?Ser?Leu?Met?Ser?His?Cys?Cys?Ala?Phe?lys?Asn?Gln?lys?lys?Ile
Downstream interface
AGA?GGA?ATC?CTT?GAG?TCC?TTG? AAG?GGC?GAG?CTC?AAG?CTT?GAA?GGT?AAG
Arg?Gly?Ile?Leu?Glu?Ser?Leu? Lys?Gly?Glu?Leu?Lys?Leu?Glu?Gly?Lys
CCT?ATC?CCT?AAC?CCT?CTC?CTC?GGT?CTC?GAT?TCT?ACG?CGT?ACC?GGT ?CAT
Pro?Ile?Pro?Asn?Pro?Leu?Leu?Gly?Leu?Asp?Ser?Thr?Arg?Thr?Gly? His
The 6*His label
CAT?CAC?CAT?CAC?CAT?TGA?GTT?TGA?TCC?GGC?TGC?TAA?CAA?AGC?CCG?AAA
His?His?His?His?His
GGA?AGC?TGA?GTT?GGC?TGC?TGC?CAC?CGC?TGA?GCA?ATA?ACT?A
(4) structure of recombinant expression plasmid pET102-hTSHRc and evaluation:
With hTSHR cThe gene directed cloning inserts pET102/D-His carrier, recombinant expression plasmid called after pET102-hTSHR cThe heat-shocked method is transformed into expresses bacterium E.coli BL21.
1. the enzyme of recombinant plasmid pET102/hTSHRc is cut evaluation:
PET 102-hTSHRc recombinant expression vector after Pst I enzyme is cut, cut the single band of 6770kb; Behind Pst I+Ndl I double digestion, cut 1469bp and 5247bp two bands, (seeing shown in Figure 4) is consistent with the Theoretical Calculation result.Among the figure;
1、2：DNA?Marker；
3: recombinant plasmid;
4:Pst I single endonuclease digestion recombinant plasmid;
5:Pst I/Ndl I double digestion recombinant plasmid.
2. the order-checking of recombinant plasmid pET 102-hTSHRc is identified
With recombinant plasmid pET 102-hTSHRc behind the purifying is template, with TrxFus is sequencing primer, this recombinant plasmid is carried out partial sequence to be measured, measure and comprise upstream and downstream interface, target gene fragment sequence at the interior 700bp of being about, the result shows that the sequence of reports such as target gene fragment and Nagayama is in full accord, direction of insertion is correct, correctly coincide with the upstream and downstream interface of pET102 carrier, guaranteed the exactness of single open reading frame.
The Trx restriction enzyme site
TTC?CTC?GAC?GCT?AAC?CTG?GCC?GGC?TCT?GGA?TCC?GGT? GAT?GAC?GAT?GAC
Phe?Leu?Asp?Ala?Asn?Leu?Ala?Gly?Ser?Gly?Ser?Gly? Asp?Asp?Asp?Asp
Upstream Interface
AAG?CTG?GGA?ATT?GAT?CCC?TT C?ACC?GCT?TTT?AAG?AAT?CAG?AAG?AAA?ATC
Lys?Leu?Gly?Ile?Asp?Pro? Phe?Thr?Ala?Phe?lys?Asn?Gln?lys?lys?Ile
AGA?GGA?ATC?CTT?GAG?TCC?TTG?ATG?TGT?AAT?GAG?AGC?AGT?ATG?CAG?AGC
Arg?Gly?Ile?Leu?Glu?Ser?Leu?Met?Cys?Asn?Glu?Ser?Ser?Met?Gln?Ser
TTG?CGC?CAG?AGA?AAA?TCT?GTG?AAT?GCC?TTG?AAT?AGC?CCC?CTC?CAC?CAG
Leu?Arg?Gln?Arg?Lys?Ser?Val?Asn?Ala?Leu?Asn?Ser?Pro?Leu?His?Gln
GAA?TAT?GAA?GAG?AAT?CTG?GGT?GAC?AGC?ATT?GTT?GGG?TAC?AAG?GAA?AAG
Glu?Tyr?Glu?Glu?Asn?Leu?Gly?Asp?Ser?Ile?Val?Gly?Tyr?lys?Glu?lys
TCC?AAG?TTC?CAG?GAT?ACT?CAT?AAC?AAC?GCT?CAT?TAT?TAC?GTC?TTC?TTT
Ser?lys?Phe?Gln?Asp?Thr?His?Asn?Asn?Ala?His?Tyr?Tyr?Val?Phe?Phe
GAA?GAA?CAA?GAG?GAT?GAG?ATC?ATT?GGT?TTT?GGC?CAG?GAG?CTC?AAA?AAC
Glu?Glu?Gln?Glu?Asp?Glu?Ile?Ile?Gly?Phe?Gly?Gln?Glu?Leu?lys?Asn
CCC?CAG?GAA?GAG?ACT?CTA?CAA?GCT?TTT?GAC?AGC?CAT?TAT?GAC?TAC?ACC
Pro?Gln?Glu?Glu?Thr?Leu?Gln?Ala?Phe?Asp?Ser?His?Tyr?Asp?Tyr?Thr
ATA?TGT?GGG?GAC?AGT?GAA?GAC?ATG?GTG?TGT?ACC?CCC?AAG?TCC?GAT?GAG
Ile?Cys?Gly?Asp?Ser?Glu?Asp?Met?Val?Cys?Thr?Pro?lys?Ser?Asp?Glu
Downstream interface
TTC?AAC?CCG?TGT?GAA?GAC?ATA?ATG?GGC?TAC?AAG?TTC?CTG?AGA?ATT? AAG
Phe?Asn?Pro?Cys?Glu?Asp?Ile?Met?Gly?Tyr?lys?Phe?Leu?Arg?Ile? Lys
GGC?GAG?CTC?AAG?CTT?GAA?GGT?AAG?CCT?ATC?CCT?AAC?CCT?CTC?CTC?GGT
Gly?Glu?Leu?Lys?Leu?Glu?Gly?Lys?Pro?Ile?Pro?Asn?Pro?Leu?Leu?Gly
The 6*His label
CTC?GAT?TCT?ACG?CGT?ACC?GGT? CAT?CAT?CAC?CAT?CAC?CAT?TGA?GTT?TGA
Leu?Asp?Ser?Thr?Arg?Thr?Gly ?His?His?His?His?His?His
TCC?GGC?TGC?TAA?CAA?AGC?CCG?AAA?GGA?AGC?TGA?GTT?GGC?TGC
Two, human thyrotropin receptor extracellular region aminoterminal, interlude and carboxyl end groups are because of expression and purifying thereof at prokaryotic system
1. the optimization of abduction delivering condition
At first fixing induction time (all getting 4 hours) adopts different IP TG concentration, and 0.2,0.4,0.5,0.6,0.8 and 1.0mML -1Fixing IPTG concentration (1.0mML again -1), adopt different induction times, 1,2,3,4,5 and 6 hour.The results are shown in Figure 5, among the figure:
1-2.pET102/D/LacZ plasmid transforms BL21 TM(DE3), do not induce abduction delivering with IPTG;
3-4.BL21 TM(DE3) empty bacterium is not induced the abduction delivering with IPTG;
5, protein molecular weight sign: 100kD, 75kD, 50kD, 35.0kD, 25.0kD, 15kD;
6-11.IPTG induction time is expressed (abduction delivering 0h, 1h, 2h, 3h, 4h, 5h and 6h) to pET102-TSHRn.
2. affinitive layer purification fusion rotein
The rough mensuration of recombinant plasmid pET102-TSHRn abduction delivering product content in the chromatography product: the SDS-PAGE photo scanning is analyzed, and fusion rotein band optical density(OD) accounts for 91.2% (seeing shown in Figure 6) of total protein band.Among the figure:
1. inclusion body lysate;
2. the inclusion body lysate is crossed post liquid;
3-10. the lavation buffer solution of different steps;
11. protein molecular weight sign: 100kD, 75kD, 50kD, 35kD, 25kD;
12-16. affinitive layer purification after product.
3 molecular weight determinations
By standard protein molecular weight and R thereof fValue derivation regression equation calculation TrxFus-TSHRn molecular weight is 37.33kD.
4. expression product is quantitative
Set up typical curve (seeing shown in Figure 7) according to the standard protein sample concentration, calculating the Trx-TSHRn productive rate is the 20.6mg/L substratum.Among the figure: y-sample OD 590nm
X-purifying rear fusion protein sample concentration.
(2) expression and purification of hTSHR-ecd interlude gene (hTSHRm) in the prokaryotic hosts bacterium
1. the optimization of abduction delivering condition
At first fixing induction time (all getting 4 hours) adopts different IP TG concentration, and 0.1,0.3,0.5,0.6,0.8 and 1.0mML -1Fixing IPTG concentration (1.0mML again -1), adopt different induction times, 1,2,3,4,5 and 6 hour.The results are shown in shown in Figure 8, among the figure:
1, protein molecular weight sign 100kD, 75kD, 50kD, 35kD, 25kD, 15kD;
2,3, the BL21 that transforms of pET102/D/LacZ plasmid TM(DE3) induce, abduction delivering not;
4,5, BL21 TM(DE3) empty bacterium is not induced and abduction delivering;
6-12,1.0mML -1IPTG induces pET102-TSHRm to express (abduction delivering 0h, 1h, 2h, 3h, 4h, 5h and 6h).
2. affinitive layer purification fusion rotein
The SDS-PAGE electrophoresis result of this section affinity chromatography product and the picture analogies of Trx-TSHRn (picture slightly).Through the gel analysis system scan, purpose fusion rotein band optical density(OD) accounts for 92.1% of total protein band optical density(OD) behind the chromatography to the SDS-PAGE photo.
3. molecular weight determination
By standard protein molecular weight and R thereof fValue derivation regression equation TrxFus-TSHRm molecular weight is 30.75D.
4. expression product is quantitative
Check in sample concentration with the protein sample OD value of measuring (after diluting) from this curve, conversing total protein concentration is 42.75mg/dl, and according to the shared per-cent of fusion rotein, calculating the Trx-TSHRm productive rate is the 35.44mg/L substratum.
(3) the hTSHR-ecd carboxyl end groups is because of (hTSHRc) expression and purification in the prokaryotic hosts bacterium
1. the optimization of abduction delivering condition
At first fixing induction time (all getting 5 hours) adopts different IP TG concentration, and 0.2,0.4,0.6,0.8 and 1.0mML -1Fixing IPTG concentration (1.0mML again -1), adopt different induction times, 1,2,3,4,5 and 6 hour.The results are shown in shown in Figure 9, among the figure:
1, protein molecular weight sign: 150kD, 100kD, 75kD, 50kD, 35kD, 25kD;
The BL21 that 2-3, pET102/D/LacZ plasmid transform TM(DE3), do not induce and abduction delivering;
4-5, BL21 TM(DE3) empty bacterium is not induced and abduction delivering;
6-12,1.0mML -1IPTG abduction delivering (0h, 1h, 2h, 3h, 4h, 5h and 6h).
2. affinitive layer purification fusion rotein
The SDS-PAGE electrophoresis result of this section affinity chromatography product and the picture analogies of Trx-TSHRn (picture slightly).This SDS-PAGE photo scanning is analyzed, and purpose fusion rotein band optical density(OD) accounted for 90.0% of total protein band optical density(OD) after chromatography was tried to achieve in calculating.
3. molecular weight determination
By standard protein molecular weight and R thereof fValue derivation regression equation.Calculating the TrxFus-TSHRc molecular weight is 28.96kD.
4. expression product is quantitative
Check in sample concentration with the protein sample OD value of measuring (after diluting) from this curve, conversing total protein concentration is 21.83mg/dl, and according to the shared per-cent of fusion rotein, calculating the Trx-TSHRc productive rate is the 28.3mg/L substratum.
Three, the evaluation of human thyrotropin receptor extracellular region aminoterminal, interlude and carboxyl terminal prokaryotic expression protein immunologic competence
(1) adopt Western blot method identifier thyrotropin receptor extracellular region aminoterminal prokaryotic expression protein immunocompetence, step is as follows:
1.SDS-PAGE electrophoresis:
Get purifying TrxTSHRn protein 20 μ l, 100V voltage, SDS-PAGE electrophoresis 4 hours.
2. commentaries on classics film:
1. cut out 6 of 1 of identical nitrocellulose filter of size and gel and 3M filter paper, soak in the water (39mmol/L glycine, 48mmol/L Tris alkali, 0.037%SDS in 6 immersions of 5 minutes Ex-all bubbles and 3M filter paper transfering buffering liquid, 20% methyl alcohol), take out filter paper.
2. the anode of electroporation is down, places 3 layers of 3M filter paper, nitrocellulose filter, gel, 3 layers of 3M filter paper from bottom to top successively, covers cloudy plate.Select electric current, 0.65mA/cm according to the gel area 2, under the room temperature, electrotransfer 2 hours.
3. sealing:
With nitrocellulose filter 20ml rinsing damping fluid (150mmol/L NaCl, 50mmol/LTris.Cl pH7.5) the room temperature rinsing is 10 minutes, repeat 3 times to remove the SDS on the nitrocellulose filter, prevent to influence antibodies afterwards, then film is placed the 5%BSA confining liquid, 4 ℃ of placements of spending the night, with the sealing not with protein bound site.
4. adding one resists:
Discard confining liquid, add positive pooled serum, normal pooled serum respectively, 4 ℃ of smooth placements 2 hours by the amount of every square centimeter of filter membrane 0.2ml.Discard antibody then, with PBS rinsing 3 times, each 10 minutes.
5. goat anti-human igg's two resistive connections with alkali phosphatase enzyme mark close:
Take out nitrocellulose filter and use 20ml rinsing damping fluid room temperature rinsing 10 minutes, abandon clean rinsing liquid, 1: the 500 goat anti-rabbit igg-AP two that presses the amount adding 5%BSA dilution of every square centimeter of filter membrane 0.2ml resists, room temperature was in conjunction with 1 hour, then filter membrane is used 20ml rinsing damping fluid rinsing 3 times, each 10 minutes.
6. colour developing:
Amount by every square centimeter of filter membrane 0.1ml adds chromogenic substrate mixture (66 μ l NBT solution, 10ml alkaline phosphatase damping fluid, 33 μ l BCIP solution), can be observed protein band in 20 minutes, sees shown in Figure 10.
(2) ELISA method identifier thyrotropin receptor extracellular region aminoterminal, interlude and carboxyl terminal prokaryotic expression protein immunocompetence
Three kinds of recombination fusion proteins with purifying are antigen, be one anti-with GD patient and normal human serum respectively, with the goat anti-human igg of horseradish peroxidase-labeled is two anti-, utilize the ELISA reaction conditions of optimizing to measure three sections recombinant protein immunocompetences, with TrxFuS-hTSHRn is antigen, 38 routine GD patients' OD value is 0.59 ± 0.14 for x ± s, the OD value x ± s of 20 routine normal controls is 0.45 ± 0.08, both have significant difference (P＜0.01), with TrxFuS-hTSHRm is that antigen GD patient OD value x ± s is 0.81 ± 0.40, normal control OD value x ± s is 1.01 ± 0.46, both there was no significant differences (P＞0.05), with TrxFuS-hTSHRc is that antigen GD patient OD value x ± s is 0.88 ± 0.25, normal control OD value x ± s is 0.64 ± 0.18, and both have significant difference (P＜0.05), and the result shows that TrxFuS-hTSHRn and TrxFuS-hTSHRc can the specificity association reaction take place with the GD patients serum, show that these two fragments have the binding site of TSAb, the former is more remarkable.
Three kinds of fusion roteins with purifying are antigen equally, with low patients (HT) of 35 routine Hashimoto thyroiditises companion first and 58 routine normal human serums is one to resist, with the goat anti-human igg of alkali phosphorus enzyme labelling is two anti-, utilizes the ELISA reaction conditions of optimizing to measure three sections protein immunization activity, and its result is as follows:
Antigen HT (normal control of x ± s) (x ± s)
TrxFuS-hTSHRn 0.66±0.24 0.42±0.12 P＜0.01
TrxFuS-hTSHRm 0.40±0.21 0.35±0.15 P＞0.05
TrxFuS-hTSHRc 1.06±0.30 0.32±0.11 P＜0.001
This shows that TrxFuS-hTSHRn and TrxFuS-hTSHRc can the specificity association reaction take place with the HT patients serum, show the binding site of these two fragment tool TSBAb, the latter is more remarkable.
Four, the foundation of the ELISA method of detection TRAb and the preliminary discussion of clinical application:
(1) foundation and the methodology that detects TRAb ELISA method identified, be antigen with TrxFuS-hTSHRn and TrxFuS-hTSHRc respectively, be one anti-with the known TSAb of containing serum and TSBAb serum (positive serum) and normal people's pooled serum (negative serum) respectively, do two with goat anti-human igg's serum of alkali phosphorus enzyme labelling and resist, successfully set up two TRAb ELISA methods.
The schedule of operation of two ELISA methods is basic identical, and is as follows:
Figure G2006100153835D00161
The optimization of ELISA condition: carry out condition experiment by the intersection serial dilution, the OD value that records with positive serum is greater than normal control OD value x+2s or be top condition more than 2 times, the antigen amount of determining ELISA is that TrxFuS-hTSHRn or TrxFuS-hTSHRc are 16ng/100ul, sample serum is dilution in 1: 200, gets 100ul; 100ul is got in alkali phosphorus enzyme labelling goat anti-human igg serum (two is anti-) dilution in 1: 20000; Developer PNPP1mg/ml gets 100ul; Termination reaction liquid 16mmol/LEDTA or 2N NaOH get 100ul.
With TrxFuS-hTSHRn is that antigenic ELISA methodology is identified: 1) get 63 routine serum, detect TSI through commodity ELISA medicine box and record the result with this method and carry out correlation analysis, as a result correlation coefficient r=0.742P＜0.05 demonstration significant correlation.2) precision: the TSAb sample homogeneous test of getting high, normal, basic content detects 8 samples respectively, and variation within batch cv% is respectively 3.96%, 4.21%, 4.67%; The TSAb sample of getting high, normal, basic content detects respectively 8 times, and batch variation cv% is respectively 7.32%, 7.94%, 8.33%.3) range of normal value: 58 routine normal people's detected result x ± s are 0.42 ± 0.12, and range of normal value is 0.18-0.66 (x ± 2s).4) detecting GD patient 95 routine x ± s is 0.90 ± 0.26, is significantly higher than normal control P＜0.01,79 routine OD value＞0.66 wherein, and positive rate is 83.16% (79/95).5) detecting HT patient 35 routine x ± s is 0.66 ± 0.24, is significantly higher than normal control P value＜0.01,21 routine OD value＞0.66 wherein, positive rate 60.0% (21/35).
With TrxFuS-hTSHRc is that antigenic ELISA methodology is identified: 1) precision: the TSBAb sample homogeneous test of getting high, normal, basic content detects 8 samples respectively, and variation within batch cv% is respectively 3.24%, 4.63%, 4.72%; The TSBAb sample of getting high, normal, basic content detects respectively 8 times, and batch variation cv% is respectively 7.22%, 8.55%, 8.09%.2) 58 routine normal people's detected result x ± s are 0.32 ± 0.11, and range of normal value is 0.10-0.54 (x ± 2s); 3) detecting HT patient 35 routine x ± s is 1.06 ± 0.30, is significantly higher than normal control P value＜0.001,33 routine OD value＞0.54 wherein, positive rate 94.2% (33/35).4) detecting GD patient 95 routine x ± s is 0.73 ± 0.21, is significantly higher than normal control P＜0.01,66 routine OD value＞0.54 wherein, and positive rate is 69.4% (66/95).
(2) clinical application: detect normal people's 108 examples altogether, 711 person-times of GD patients, first visit patient 436 examples wherein are with hTSHR nAnd hTSHR cTwo ELISA methods setting up for antigen detect every batch sample total positives rate 77.7%-93.3% simultaneously; HT first visit patient 35 examples, two ELISA methods detect every batch sample total positives rate 94.2-97.1% simultaneously; Nontoxic nodular goiter patient 6 examples, total positives rate 0%.
The amino terminal sequence table
＜110〉General Hospital of Tianjin Medical Univ.
＜120〉human thyrotropin receptor extracellular region aminoterminal gene expression product and preparation method and the application of this product in enzyme immune technology
<160>1
<210>1
<211>462
<212>DNA
＜213〉Genus Homo (Homo)
<220>
<221>CDS
<222>(164)...(625)
<400>1
ATG?GGG?TGT?TCG?TCT?CCA?CCC?TGC?GAG?TGC?CAT?CAG?GAG?GAG?GAC?TTC?211bp
Met?Gly?Cys?Ser?Ser?Pro?Pro?Cys?Glu?Cys?His?Gln?Glu?Glu?Asp?Phe?16AA
1 7 13
AGA?GTC?ACC?TGC?AAG?GAT?ATT?CAA?CGC?ATC?CCC?AGC?TTA?CCG?CCC?AGT?259bp
Arg?Val?Thr?Cys?lys?Asp?Ile?Gln?Arg?Ile?Pro?Ser?Leu?Pro?Pro?Ser?32AA
19 25 31
ACG?CAG?ACT?CTG?AAG?CTT?ATT?GAG?ACT?CAC?CTG?AGA?ACT?ATT?CCA?AGT?307bp
Thr?Gln?Thr?Leu?lys?Leu?Ile?Glu?Thr?His?Leu?Arg?Thr?Ile?Pro?Ser?48AA
37 43
CAT?GCA?TTT?TCT?AAT?CTG?CCC?AAT?ATT?TCC?AGA?ATC?TAC?GTA?TCT?ATA?355bp
His?Ala?Phe?Ser?Asn?Leu?Pro?Asn?Ile?Ser?Arg?Ile?Tyr?Val?Ser?Ile?64AA
49 55 61
GAT?GTG?ACT?CTG?CAG?CAG?CTG?GAA?TCA?CAC?TCC?TTC?TAC?AAT?TTG?AGT?403bp
Asp?Val?Thr?Leu?Gln?Gln?Leu?Glu?Ser?His?Ser?Phe?Tyr?Asn?Leu?Ser?80AA
67 73 79
AAA?GTG?ACT?CAC?ATA?GAA?ATT?CGG?AAT?ACC?AGG?AAC?TTA?ACT?TAC?ATA?451bp
lys?Val?Thr?His?Ile?Glu?Ile?Arg?Asn?Thr?Arg?Asn?Leu?Thr?Tyr?Ile?96AA
85 91
GAC?CCT?GAT?GCC?CTC?AAA?GAG?CTC?CCC?CAC?CTA?AAG?TTC?CTT?GGC?ATT?499bp
Asp?Pro?Asp?Ala?Leu?lys?Glu?Leu?Pro?His?Leu?lys?Phe?Leu?Gly?Ile?112AA
97 103 109
TTC?AAC?ACT?GGA?CTT?AAA?ATG?TTC?CCT?GAC?CTG?ACC?AAA?GTT?TAT?TCC?547bp
Phe?Asn?Thr?Gly?Leu?lys?Met?Phe?Pro?Asp?Leu?Thr?lys?Val?Tyr?Ser?128AA
115 121 127
ACT?GAT?ATA?TTC?TTT?ATA?CTT?GAA?ATT?ACA?GAC?AAC?CCT?TAC?ATG?ACG?595bp
Thr?Asp?Ile?Phe?Phe?Ile?Leu?Glu?Ile?Thr?Asp?Asn?Pro?Tyr?Met?Thr?144AA
133 139
TCA?ATC?CCT?GTG?AAT?GCT?TTT?CAG?GGA?CTA 625bp
Ser?Ile?Pro?Val?Asn?Ala?Phe?Gln?Gly?Leu 154AA
145 151

Claims (5)

1. human thyrotropin receptor extracellular region aminoterminal gene hTSHR-N expression product, it is characterized in that this hTSHR-N fragment express acquisition can with the warm albumen TrxFus-hTSHRn of TRAb bonded recombinant fragment, its aminoacid sequence is:
Met?Gly?Cys?Ser?Ser?Pro?Pro?Cys?Glu?Cys?His?Gln?Glu?Glu?Asp?Phe 16AA
1 7 13
Arg?Val?Thr?Cys?lys?Asp?Ile?Gln?Arg?Ile?Pro?Ser?Leu?Pro?Pro?Ser 32AA
19 25 31
Thr?Gln?Thr?Leu?lys?Leu?Ile?Glu?Thr?His?Leu?Arg?Thr?Ile?Pro?Ser 48AA
37 43
His?Ala?Phe?Ser?Asn?Leu?Pro?Asn?Ile?Ser?Arg?Ile?Tyr?Val?Ser?Ile 64AA
49 55 61
Asp?Val?Thr?Leu?Gln?Gln?Leu?Glu?Ser?His?Ser?Phe?Tyr?Asn?Leu?Ser 80AA
67 73 79
lys?Val?Thr?His?Ile?Glu?Ile?Arg?Asn?Thr?Arg?Asn?Leu?Thr?Tyr?Ile 96AA
85 91
Asp?Pro?Asp?Ala?Leu?lys?Glu?Leu?Pro?His?Leu?lys?Phe?Leu?Gly?Ile 112AA
97 103 109
Phe?Asn?Thr?Gly?Leu?lys?Met?Phe?Pro?Asp?Leu?Thr?lys?Val?Tyr?Ser 128AA
115 121 127
Thr?Asp?Ile?Phe?Phe?Ile?Leu?Glu?Ile?Thr?Asp?Asn?Pro?Tyr?Met?Thr 144AA
133 139
Ser?Ile?Pro?Val?Asn?Ala?Phe?Gln?Gly?Leu 154AA
145 151
2. human thyrotropin receptor extracellular region aminoterminal gene expression product according to claim 1, it is characterized in that this expression product is to exist with warm albumen form, warm albumen TrxFus-hTSHRn molecular weight is 34.4kD, and wherein the Trx molecular weight is 13.2kD.
3. human thyrotropin receptor extracellular region aminoterminal gene expression product according to claim 1 and 2, the purity that it is characterized in that this expression product is 91.2%, productive rate is the 20.6mg/L substratum.
4. the preparation method of the human thyrotropin receptor extracellular region aminoterminal gene expression product of a claim 1, extract total RNA in the parathyroid tissue that it is characterized in that downcutting by Graves ' patient operative treatment, synthetic and amplify hTSHR-N end encoding gene through RT-PCR, with the directed cloning technology goal gene is inserted carrier pET102/D-His, with the heat-shocked method with constructed expression vector Transformed E .coli TOP10, screen positive bacterium colony, extracting recombinant expression plasmid pET102/hTSHRn is transformed in the E.coli BL21 prokaryotic expression bacterium, expression condition is an inductor with isopropylthio β-D-galactoside IPTG, concentration 0.4-1.2mML -1, 25 ℃-37 ℃ of temperature, time 1-12 hour; Expression product is mainly the inclusion body form, so pass through Ni under the sex change condition 2+The warm albumen of-NTA affinitive layer purification obtains warm albumen TrxFus-hTSHRn through the dialysis renaturation again.
5. the purposes of the human thyrotropin receptor extracellular region aminoterminal gene hTSHR-N expression product of claim 1 is characterized in that the hTSHR-N end group of hTSHR-ecd gene is applied in enzyme immunoassay technology ELISA because of expression product.
CN200610015383A 2006-08-22 2006-08-22 Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology Expired - Fee Related CN1952137B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200610015383A CN1952137B (en) 2006-08-22 2006-08-22 Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200610015383A CN1952137B (en) 2006-08-22 2006-08-22 Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology

Publications (2)

Publication Number Publication Date
CN1952137A CN1952137A (en) 2007-04-25
CN1952137B true CN1952137B (en) 2010-05-12

Family

ID=38058695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610015383A Expired - Fee Related CN1952137B (en) 2006-08-22 2006-08-22 Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology

Country Status (1)

Country Link
CN (1) CN1952137B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101692085A (en) * 2009-09-11 2010-04-07 天津医科大学总医院 Method for quantitatively detecting TRAb plate-type fluorescent enzyme immunity and application thereof
CN108761085A (en) * 2018-05-24 2018-11-06 成都医学院 The enzyme linked immunological kit and detection method of thyrotropin receptor parting antibody can be detected simultaneously
CN110579593A (en) * 2019-09-17 2019-12-17 郑州安图生物工程股份有限公司 kit for detecting concentration of stimulated thyroid stimulating hormone receptor antibody
CN111548422B (en) * 2020-05-26 2023-04-07 郑州伊美诺生物技术有限公司 Human thyroid stimulating hormone receptor fusion protein and preparation method and application thereof
CN115925966A (en) * 2021-09-22 2023-04-07 厦门英博迈生物科技有限公司 Recombinant thyroid stimulating hormone receptor protein, preparation method and application

Also Published As

Publication number Publication date
CN1952137A (en) 2007-04-25

Similar Documents

Publication Publication Date Title
CN101294964B (en) Reagent and method for detecting active tuberculosis and tuberculosis dormant infection
CN1952137B (en) Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology
CN104198741A (en) Tilapia streptococcus agalactiae IgM antibody capture ELISA detection kit
CN105542014A (en) TP recombinant antigen and preparing method and application thereof
CN106279378A (en) Varicella zoster virus gE antigen and the purposes in detection varicella zoster virus antibody thereof
CN107304231B (en) Mycobacterium tuberculosis fusion protein and application thereof
CN101970463A (en) Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
RU2360926C9 (en) HYBRID PROTEIN CFP10-ESAT6, INDUCING REACTION OF HYPERSENSITIVITY OF DELAYED TYPE WITH RESPECT TO M.Tuberculosis, CODING IT CHIMERIC NUCLEIC ACID AND RECOMBINANT PLASMID EXPRESSION VECTOR, CONTAINING IT, METHOD OF OBTAINING HYBRID PROTEIN AND BASED ON IT DOSED MEDICINAL FORM FOR INTRACUTANEOUS INJECTION
CN1952136A (en) Gene expression product of extro-cellular domain carboxyl end of human thyrotropin receptor, its preparing method and application in enzyme immune technology
CN106841607B (en) Acute Hepatopancreatic necrosis syndrome dedicated test kit and preparation method thereof
CN106397551A (en) Treponema pallidum infection dependent antigens and kits and applications thereof
CN108440656A (en) The application of mycobacterium tuberculosis PKA albumen and its fusion protein in auxiliary diagnosis pulmonary tuberculosis
CN101798351B (en) Recombinant expression of human TIM-1-Fc fusion protein
CN103965348B (en) Monopterus albus (Zuiew) estrogen receptorαgene, encoding proteins and enzyme-linked immune detection method
CN101266252A (en) Paragonimiasis detection device and method for making same
CN102432673A (en) Brucella bp26 protein epitope and monoclonal antibody and application thereof
KR20060129229A (en) Surface-located campylobacter jejuni polypeptides
CN101805397A (en) Mycobacterium tuberculosis ESAT-6 recombinant dipolymer, preparation method and application thereof
CN104086628A (en) Monoclonal antibody of brucella omp31 protein and application thereof
CN111363031B (en) pSer131 polyclonal antibody of BNIP3, preparation method and application thereof
CN101266253A (en) Paragonimiasis detection reagent kit and method for making same
CN106995801B (en) Anti-tree shrew CD4 molecular monoclonal antibody, hybridoma cell strain secreting antibody and application
CN104725492A (en) Immunity-protective Acinetobacter baumannii surface antigen SurAl
CN100406472C (en) Fusion and solubility expression of cobratoxin and acidolysis release and purification of recombinant toxin
CN110655575B (en) Epitope polyclonal antibody of toxoplasma gondii Actin protein and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100512

Termination date: 20210822

CF01 Termination of patent right due to non-payment of annual fee